R&D Support Laboratory Support Project for Global Competitiveness of SMEs in the Field of Life Sciences, Kacır, Member of the European Union (EU) Commission Responsible for Innovation, Research, Culture, Education and Youth, Iliana Ivanova and Rector of Boğaziçi University, Prof. DR . It was presented at the meeting attended by Mehmet Naci İnci and academics.
Wishing for a promising and promising project that will take the country's production and technology development capacity in life sciences to the next level, ensure the construction of critical infrastructure and provide new and unique gains for the healthcare industry, Kacır stated that the economic independence of a country corresponds to its technological competence.
Stating that countries that produce added value and have an innovative ecosystem have a greater say on the international stage, Kacır explained that they see technological change as an opportunity for Turkey to improve its ability to produce competitive products and services at a high level To offer quality technology areas in line with the National Technology Move objectives.
Stating that they are proceeding with the approach of building an ecosystem that supports technological innovation and research while strengthening the skilled human resources of the sector, Kacır said that they aim to increase the number of patents in clinical and information technologies, R&D To increase spending and number of patents initiatives in the health sector with the roadmap for smart life and health products and technologies, he explained
“We have supported 56 investment projects with a total size of over 22 billion lira”
Stating that they accelerated the localization movement in the areas of pharmaceuticals, medical devices and health information technologies, which they considered critical and strategic, Mehmet Fatih Kacır said: “Last year alone, we issued 404 investment incentive certificates in the healthcare sector, exceeding mobilization. “62 billion lira in investments and the creation of around 11,000 skilled jobs,” said.
Kacır pointed out that they have supported 56 investment projects with a total volume of over 22 billion lira, ranging from biosimilar drugs to biosimilar cancer and biosimilar drugs, within the framework of the technology-oriented industrial movement program implemented to promote value-added production and reduce the current account deficit Autoimmune drugs, from orthopedic devices and prostheses to innovative generics.
Stating that R&D and innovation expertise is a must for a strong healthcare production infrastructure, Kacır continued as follows:
“We conduct more than 1,700 research projects in 69 R&D centers of our leading healthcare companies, particularly in the areas of pharmaceuticals, medical devices and medicine. To date, more than 3,700 technology startups in our Technoparks have contributed to more than 21,000.” In our TÜBİTAK funding programs, we focus on studies in the health sector under the headings of research and development. Within the framework of our TÜBİTAK scholarship and funding programs, more than 9,500 projects are carried out in the field of health technologies and nearly 17,000 people have received a total of 41 billion in the last 22 years. “We have provided TL support and paved the way for the development of new healthcare solutions by conducting qualified research and development studies in the field of healthcare technologies.”
“Exemplary and groundbreaking work has been done at Boğaziçi LifeSci”
Minister Kacır stated that advanced research activities in breakthrough technologies in the field of life sciences are being carried out at Boğaziçi LifeSci, which has been carrying out exemplary and groundbreaking work in many aspects since 2010.
Noting that the center's researchers have carried out more than 100 scientific research projects and produced a total of 1200 high-impact value publications, Kacır said, “Our Prof. Dr. Rana Sanyal and his team; “The ministry has promoted the development of our country.” “It is the first drug candidate approved by the Turkish Medicines and Medical Devices Authority (TITCK),” he said.
Stating that the significance of this success story lies not only in the discovery of a drug that gives hope to patients on a global scale, Kacır added: “It is also valuable that we managed to deliver a molecule from the laboratory to patients for the first time deliver.” time with our own resources, and that this has proven to be feasible. said.
Stating that today there are more than 120 healthcare startups in the world with a valuation of more than a billion dollars, Kacır said, “Our country's technology ecosystem has so far produced seven technology startups, Turcorns as we call them, that have a valuation billions of dollars, but we have not yet been able to introduce Turcorn into healthcare. I believe that the pharmaceutical phase developed by our teacher and his team will successfully complete the Phase 2 and Phase 3 trials. The initiative of which he is the founder will become a success story on a global scale,” has given his assessment .
Kacır, Prof. DR. He explained that Sanyal's project was included in the Turcorn 100 program, which was created to support Turkish technology startups with rapid growth potential on a global scale, scale faster and open to global markets.
Pointing out that they supported the R&D Support Laboratories Support Project on Global Competitiveness of Life Sciences SMEs under the Competitive Sectors Program, Kacır said:
“With this project, implemented with a new investment of 5 million euros, we offered exemplary infrastructure, including Turkey's first preclinical animal imaging center, a pilot production and first-scale production facility, as well as a clean room according to international standards. in the service of our entrepreneurs and researchers.”
Kacır pointed out that they have created thematic incubation and acceleration programs to support entrepreneurs and SMEs, adding that the project will accelerate the value-added and technology-oriented transformation of the country's economy.
Bir yanıt yazın